课题基金 / 基金详情

The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.

The TACtful Trial: A first-in-human multi-centre trial of BCMA specific T-cell antigen coupler infusion, generated from cryopreserved G-CSF-mobilized peripheral blood, in patients with relapsed and refractory multiple myeloma.
TACtful 试验：首次在复发性和难治性多发性骨髓瘤患者中进行 BCMA 特异性 T 细胞抗原偶联剂输注的人体多中心试验，该抗体由冷冻保存的 G-CSF 动员的外周血产生。
批准号：
478892
负责人：
Hay Annette
金额：
$222.64万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-03-01 至 2028-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=478892&lang=en
关键词：
Biomanufacturing Cancer Cell Therapy Clinical Trial First-In-Human Immunotherapy Multiple Myeloma Relapsed And Refractory Synthetic Androgen Receptor

项目摘要

项目成果

Hay Annette的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Multiple myeloma is an incurable cancer. Typically, patients receive continuous treatment for years until it stops working requiring frequent hospital visits. Novel immune therapies have been developed where cancer patients' own white blood cells are engi
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase III Non-Inferiority Randomized Controlled Trial (RCT) of Fixed-Duration Daratumumab Versus Continuous Daratumumab Among Transplant Ineligible Older Adults with Newly-Diagnosed Multiple Myeloma
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Canadian Cell Therapies Workshop 2019
国内基金
海外基金
中国北方人群肺癌患者Cancer/Testis抗原表达谱绘制表位鉴定及功能性抗原特异性CTL制备研究
  • 批准号：
    81673007
  • 项目类别：
    面上项目
  • 资助金额：
    54.0万元
  • 批准年份：
    2016
  • 负责人：
    金时
  • 依托单位：
    哈尔滨医科大学